Head-To-Head Comparison: Valion Bio, Inc. Common Stock (NASDAQ:VBIO) versus Halozyme Therapeutics (NASDAQ:HALO)

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Valuation & Earnings

This table compares Valion Bio, Inc. Common Stock and Halozyme Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	0.64	-$8.88 million	($159.25)	-0.00
Halozyme Therapeutics	$1.40 billion	10.62	$316.89 million	$3.35	39.00

Halozyme Therapeutics has higher revenue and earnings than Valion Bio, Inc. Common Stock. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Valion Bio, Inc. Common Stock and Halozyme Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
Halozyme Therapeutics	1	2	9	1	2.77

Halozyme Therapeutics has a consensus price target of $99.55, suggesting a potential downside of 23.82%. Given Halozyme Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Profitability

This table compares Valion Bio, Inc. Common Stock and Halozyme Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
Halozyme Therapeutics	24.86%	260.98%	23.91%

Institutional & Insider Ownership

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 0.9% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.

Summary

Halozyme Therapeutics beats Valion Bio, Inc. Common Stock on 14 of the 15 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.